secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061119
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q3 net loss $48.5M; XEN1101 MDD trial topline due late Nov–mid Dec
------------------------------------------------------------------------

- Net loss $48.5M in Q3 2023 vs $37.2M in Q3 2022; cash $639.1M, funding operations into 2026.
- XEN1101 Phase 2 X-NOVA MDD trial topline results expected late November to mid-December 2023.
- Phase 3 epilepsy trials X-TOLE2, X-TOLE3, X-ACKT ongoing; X-TOLE2 enrollment to complete H2 2024.
- Neurocrine to report NBI-921352 adult focal study data in November 2023.
- R&D expenses increased to $42.9M from $29.4M, driven by XEN1101 clinical advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/0000950170-23-061119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/xene-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer